A method of treating dry AMD in a subject comprising administering to the subject a therapeutically effective amount of an anti-inflammatory to thereby treat the dry AMD is disclosed. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of one or more anti-inflammatory and a pharmaceutically acceptable carrier, diluent or excipient when used to treat dry AMD and use of the pharmaceutical composition for the manufacture of a medicament for the treatment of dry AMD. The one or more anti-inflammatory may comprise one or more of a COX inhibitor, one or more mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, one or more glucocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, an antileukotrine and/or a leukotriene receptor antagonist. In one embodiment the anti-inflammatory comprises fludrocortisone.
